13:56 30/09/2014 Stocks to Watch- 3M Co (NYSE:MMM), Arena Pharmaceuticals, Inc. (NASDAQ ...
Stocks to Watch- 3M Co (NYSE:MMM), Arena Pharmaceuticals, Inc. (NASDAQ ...
Techsonian (press release) - 15 hours ago
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600 ...

12:14 30/09/2014 News Review -Arena Pharmaceuticals, Inc. (NASDAQ:ARNA),McEwen Mining ...
News Review -Arena Pharmaceuticals, Inc. (NASDAQ:ARNA),McEwen Mining ...
Techsonian (press release) - 16 hours ago
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showing optimistic movement during previous trade, it traded with the volume of 2.85 million shares in the last trading session, as compared to average volume of 4.66 million shares.

12:48 29/09/2014 Watch List : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Petroleo Brasileiro ...
Watch List : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Petroleo Brasileiro ...
Tech News - Sep 29, 2014
Credit Suisse initiated coverage on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a research report released on Thursday morning.

15:15 19/09/2014 Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
TheStreet.com - Sep 19, 2014
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.

12:16 19/09/2014 Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5%
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5%
Zacks.com - Sep 19, 2014
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.

15:51 17/09/2014 5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Motley Fool - Sep 17, 2014
Arena Pharmaceuticals (NASDAQ: ARNA ) held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline.
Belviq And Phentermine Study Awes Some Investors - Should It? (ARNA) - Seeking Alpha (registration)

15:03 15/09/2014 Arena Down On The Back Of Weigh-Loss Drug Failure
Arena Down On The Back Of Weigh-Loss Drug Failure
Bidness ETC - Sep 15, 2014
The biotech sector has performed well this year, with Intercept Pharmaceuticals Inc. (ICPT) and Gilead Sciences, Inc. (GILD) topping the list. Most biopharmaceuticals have so far registered positive gains in 2014, after overcoming the momentum sell-off ...
FDA panel backs Novo Nordisk drug for obesity - Daily Item
FDA Backs Injection for Obesity - Drug Discovery & Development

14:10 12/09/2014 Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Motley Fool - Sep 12, 2014
Arena Pharmaceuticals (NASDAQ: ARNA ) and Orexigen's (NASDAQ: OREX ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And Vivus's ... - Bidness ETC
New anti-obesity drug is OK'd - Nashua Telegraph

14:46 09/09/2014 Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Motley Fool - Sep 9, 2014
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Arena Pharmaceuticals - A Biotech Value Investment - Seeking Alpha (registration)
Investor's Watch List –Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Image ... - Techsonian (press release)

13:07 02/09/2014 Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
MarketWatch - Sep 2, 2014
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, +3.41% today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog - NASDAQ